SPDR Series Trust. Holdings as of Jun 30, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| State Street Global AdvisorsCash or money market | 5.87% | $630.64M | 630,641,937 |
| Apogee Therapeutics Inc | 1.49% | $159.76M | 1,203,674 |
| Moderna IncMRNA | 1.41% | $151.61M | 2,164,892 |
| Twist Bioscience CorpTWST | 1.41% | $151.14M | 1,469,111 |
| Oruka Therapeutics IncORKA | 1.38% | $147.99M | 1,555,002 |
| Kymera Therapeutics IncKYMR | 1.36% | $145.95M | 1,272,754 |
| Viking Therapeutics IncVKTX | 1.30% | $139.97M | 3,587,998 |
| Praxis Precision Medicines IncPRAX | 1.29% | $138.52M | 413,737 |
| Erasca IncERAS | 1.27% | $136.43M | 7,447,165 |
| Revolution Medicines IncRVMD | 1.20% | $129.32M | 690,499 |
| Rhythm Pharmaceuticals IncRYTM | 1.20% | $128.98M | 1,161,672 |
| CG oncology IncCGON | 1.20% | $128.81M | 1,812,932 |
| SELLAS Life Sciences Group IncSLS | 1.19% | $127.74M | 8,654,720 |
| Vaxcyte IncPCVX | 1.19% | $127.43M | 2,192,112 |
| Dianthus Therapeutics IncDNTH | 1.18% | $127.01M | 1,302,913 |
| Cytokinetics IncCYTK | 1.18% | $126.46M | 1,484,466 |
| Natera IncNTRA | 1.16% | $124.85M | 459,937 |
| Scholar Rock Holding CorpSRRK | 1.16% | $124.20M | 2,258,236 |
| Roivant Sciences Ltd | 1.16% | $124.03M | 3,504,648 |
| Mirum Pharmaceuticals IncMIRM | 1.16% | $124.00M | 1,059,206 |
| Cogent Biosciences IncCOGT | 1.14% | $122.79M | 3,172,989 |
| Ultragenyx Pharmaceutical IncRARE | 1.14% | $122.44M | 3,666,868 |
| Travere Therapeutics IncTVTX | 1.13% | $121.01M | 2,130,135 |
| Alkermes PLC | 1.11% | $119.00M | 2,271,185 |
| Krystal Biotech IncKRYS | 1.10% | $118.47M | 318,741 |
| Celcuity IncCELC | 1.10% | $118.05M | 1,128,339 |
| Relay Therapeutics IncRLAY | 1.10% | $117.96M | 6,304,701 |
| Spyre Therapeutics IncSYRE | 1.10% | $117.73M | 1,326,035 |
| TG Therapeutics IncTGTX | 1.09% | $117.34M | 2,135,715 |
| Beam Therapeutics IncBEAM | 1.08% | $115.87M | 3,376,280 |
| Insmed IncINSM | 1.08% | $115.55M | 1,083,724 |
| Protagonist Therapeutics IncPTGX | 1.07% | $115.39M | 941,367 |
| Arrowhead Pharmaceuticals IncARWR | 1.07% | $114.73M | 1,407,587 |
| Vera Therapeutics IncVERA | 1.06% | $113.72M | 2,650,187 |
| Vertex Pharmaceuticals IncVRTX | 1.06% | $113.49M | 228,475 |
| Madrigal Pharmaceuticals IncMDGL | 1.06% | $113.43M | 211,251 |
| AbbVie IncABBV | 1.04% | $111.38M | 442,603 |
| Biogen IncBIIB | 1.03% | $110.74M | 512,556 |
| PTC Therapeutics IncPTCT | 1.03% | $110.73M | 1,357,466 |
| Halozyme Therapeutics IncHALO | 1.03% | $110.55M | 1,412,358 |
| uniQure NV | 1.03% | $110.38M | 2,396,361 |
| Bridgebio Pharma IncBBIO | 1.02% | $110.02M | 1,477,181 |
| CRISPR Therapeutics AG | 1.02% | $109.84M | 2,013,860 |
| ImmunityBio IncIBRX | 1.02% | $109.40M | 12,496,050 |
| Summit Therapeutics IncSMMT | 1.01% | $108.59M | 7,453,137 |
| Ionis Pharmaceuticals IncIONS | 1.00% | $107.68M | 1,358,012 |
| Incyte CorpINCY | 1.00% | $107.12M | 944,922 |
| Amgen IncAMGN | 0.99% | $106.78M | 294,863 |
| Neurocrine Biosciences IncNBIX | 0.97% | $104.32M | 618,966 |
| Gilead Sciences IncGILD | 0.96% | $103.54M | 819,573 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.